Skip to Content

IP 253 (Ranitidine 150 mg)

Pill imprint IP 253 has been identified as Ranitidine hydrochloride 150 mg.

Ranitidine is used in the treatment of gerd; zollinger-ellison syndrome; erosive esophagitis; duodenal ulcer; eczema (and more), and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Ranitidine 150 mg is not a controlled substance under the Controlled Substance Act (CSA).

Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride 150 mg IP 253  Front
Ranitidine hydrochloride 150 mg IP 253  Back
Ranitidine hydrochloride 150 mg IP 253
Ranitidine hydrochloride
Imprint:
IP 253
Strength:
150 mg
Color:
Orange
Size:
9.00 mm
Shape:
Round
Availability:
Rx and/or OTC
Drug Class:
H2 antagonists
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Manufacturer:
Amneal Pharmaceuticals
National Drug Code (NDC):
53746-0253
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
63739-0489 McKesson Packaging Services
68084-0717 Amerisource Health Services
42291-0724 AvKare, Inc.
66267-0188 Nucare Pharmaceuticals Inc (repackager)
68071-1321 Nucare Pharmaceuticals Inc (repackager)

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide